Background
==========

The most common epigenetic alteration in human cancer affecting gene expression is 5\'-cytosine methylation within CpG islands in gene promoter regions \[[@B1]\]. Promoter methylation effectively represses RNA transcription and occurs in many genes involved in human cancer development \[[@B2]\]. The majority of these affected genes are potential or known tumor suppressor genes that are regulators of different cellular pathways, such as cell cycle, DNA repair, growth factor signaling or cell adhesion \[[@B3]\]. Wnt signaling is one of the central cellular pathways commonly disrupted in several tumor types, including breast cancer \[[@B4],[@B5]\]. Unlike colorectal cancer, evidence for genetic alterations of Wnt pathway components in breast cancer, such as adenomatous polyposis coli (*APC*) mutations, is rare \[[@B6]\]. Several lines of evidence suggest that in breast cancer the Wnt signaling pathway is disrupted predominantly through epigenetic aberrations, most of all by promoter methylation of genes encoding secreted Wnt inhibitory molecules. For instance, genes encoding secreted frizzled-related proteins (SFRP) and Wnt-inhibitory factor-1 (*WIF1*) were previously reported as frequent targets of epigenetic inactivation in breast cancer \[[@B7]-[@B12]\]. In addition to this, we have recently shown that the putative Wnt signaling inhibitor Dickkopf-3 (*DKK3*) is functionally inactivated by promoter methylation in more than 60% of tumors from patients with invasive breast cancer \[[@B13]\]. Besides secreted inhibitors, two studies also reported frequent methylation of the *APC*gene in breast carcinomas \[[@B14],[@B15]\]. Altogether, this provides strong evidence for an epigenetically disrupted and thereby activated Wnt signaling pathway in the development of human breast cancer.

There is increasing evidence that promoter methylation of cancer-related genes can be one of the most prevalent molecular markers for human cancer diseases \[[@B16]\]. The potential clinical applications of DNA-methylation biomarkers may include diagnosis of neoplasm, tumor classification, prediction of response to treatment, or patient prognosis \[[@B17]\]. Methylation of particular Wnt pathway genes has already been described as a potential biomarker for unfavorable patient outcome in human cancer. For instance, we have recently shown that methylation of *SFRP1*as well as *SFRP5*is associated with reduced patient overall survival in breast cancer \[[@B7],[@B10]\]. In contrast to this, high-frequent methylation of *SFRP2*was not prognostically relevant in breast cancer \[[@B9]\], but was shown to comprise a diagnostic value as a sensitive screening marker for the stool-based detection of colorectal cancer and premalignant colorectal lesions \[[@B18]-[@B20]\]. *DKK3*methylation is associated with reduced DFS in acute lymphoblastic leukemia \[[@B21]\], and also with shorter OS in kidney cancer \[[@B22]\] and non-small cell lung cancer \[[@B23]\], as well as very recently reported with OS in gastric cancer \[[@B24]\]. Taken together, promoter methylation of Wnt signaling antagonists appears to provide a rich pool of novel tumor biomarkers in human cancer, potentially useful in the clinical setting by helping to improve management of this disease.

In the present study, we addressed the question to whether promoter methylation of two Wnt antagonist genes (*WIF1*and *DKK3*), that were previously reported as hypermethylated in breast cancer, provides prognostically relevant information in this tumor entity. In univariate and multivariate analyses we have investigated gene methylation in a large cohort (n = 150) of invasive breast cancer specimens. We here demonstrate for the first time that *DKK3*methylation, but not *WIF1*methylation, is an independent prognostic factor indicating poor patient survival in human breast cancer.

Methods
=======

Patient material
----------------

Surgically resected samples were obtained from 150 unselected breast cancer patients at the Departments of Gynecology at the University Hospitals of Aachen, Jena, Regensburg and Düsseldorf in Germany from 1991 to 2005. For 19 patients, normal breast tissues were available. In all cases, at least two-board certified pathologists agreed on the diagnosis on breast cancer. The samples were recruited in a non-selective, consecutive manner. Cases were not stratified for any known pre-operative or pathological prognostic factor. Inclusion criteria for the study were: Female patients presenting with unilateral, primary invasive breast cancer without individual breast cancer history. Exclusion criteria were: neo-adjuvant chemotherapy prior to surgery, presentation with secondary breast cancer, or peritumorous carcinoma *in situ*present in the tumor sample. All patients gave informed consent for retention and analysis of their tissue for research purposes and the Institutional Review Boards of the participating centers approved the study. Tumor histology was determined according to the criteria of the WHO (2003), while disease stage was assessed according to UICC \[[@B25]\]. Histological, tumors were graded according to Bloom and Richardson, as modified by Elston and Ellis \[[@B26]\]. Hormone receptor status was assessed according to the scoring system developed by Remmele and Stegner \[[@B27]\]. For 125 patients follow-up data were available with a median time of 64 months (range 1 to 174 months). Patient characteristics of this cohort have been previously described \[[@B13]\].

Extraction of genomic DNA
-------------------------

Tumor material was snap-frozen in liquid nitrogen immediately after surgery. Hematoxylin/Eosin-stained sections were prepared for assessing the percentage of tumor cells; only samples with \> 70% tumor cells were selected. A total of 20 tissue sections (20 μm each) per specimen was dissected in a cryotom and pooled. Normal breast tissue specimens were prepared likewise. For normal breast samples, the epithelial cell amount had to exceed 30% in order to be selected for further preparation. Samples were dissolved in lysis buffer followed by DNA isolation, using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s recommendations. The extracted genomic DNA was finally diluted in 55 μl of Tris buffer (10 mM; pH 7.6).

*In silico*promoter analysis
----------------------------

The *WIF1*promoter, located at chromosome position 12q14.2, was investigated according to the contig ENSG00000156076 contained in the Ensembl database \[[@B28]\]. A genomic nucleotide sequence consisting of 1000 bp upstream of the annotated transcription start site (TSS) and 293 bp downstream of the TSS (first exon) was analyzed by methprimer software \[[@B29]\]. Criteria for CpG island prediction were adjusted to the definition from Takai and Jones \[[@B30]\], and included an observed/expected CpG ratio of ≥ 0.7 and a GC content of ≥ 60%. The identified CpG island proximal to the TSS was chosen for promoter methylation analysis. Methylation-specific PCR (MSP) primers were derived from a particular region within this island, which has been analyzed for CpG methylation by bisulfite genomic sequencing (BGS) in a previous study \[[@B11]\]. The *DKK3*promoter, located at chromosome position 11p15.3, was investigated according to the contig ENSG00000050165 contained in the Ensembl database. A genomic nucleotide sequence consisting of 1000 bp upstream of the annotated TSS and 1001 bp downstream of the TSS was analyzed by methprimer software. The downstream region covered the first three exons of the gene, since *DKK3*was reported to be alternatively transcribed under the control of two distinct promoters \[[@B31]\]. Methprimer software identified the existence of two distinct CpG islands, located proximal to either of the two predicted transcription start sites. The downstream CpG island was chosen for promoter methylation analysis, since the shorter *DKK3*transcript was shown to be more commonly distributed in normal human tissues \[[@B31]\].

Bisulfite-modification and methylation-specific PCR
---------------------------------------------------

Approximately 1 μg of genomic DNA was bisulfite-modified using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer\'s recommendations. The bisulfite-converted DNA was finally eluted in 20 μl of Tris buffer (10 mM; pH 7.6). Methylation-specific PCR was performed according to Herman *et al*. \[[@B32]\]. In short, 1 μl of modified DNA (\~50 ng) was amplified using MSP primers (see Table [1](#T1){ref-type="table"}) that specifically recognized either the unmethylated or methylated promoter sequences after bisulfite conversion \[[@B32]\]. Reaction volumes of 25 μl contained 1 × MSP-buffer \[[@B33]\], 400 nM of each primer, and 1.25 mM of each dNTP. One drop of mineral oil was added to each reaction tube. The PCR was initiated as \"Hot Start\" PCR at 95°C and held at 80°C before the addition of 1.25 units *Taq*DNA polymerase (Promega, Madison, WI). Cycle conditions were: 95°C for 5 min, 34 cycles of 95°C for 30 sec, 55°C (58°C) for 30 sec, 72°C for 40 sec and a final extension at 72°C for 5 min. Amplification products were visualized on 3% low range ultra agarose gel (Bio-Rad Laboratories, Hercules, CA) containing ethidium bromide and illuminated under ultraviolet light. Specificity of MSP primers in detecting the promoter methylation status were demonstrated by use of universal unmethylated and universal poly-methylated DNA as template (Epi Tect Control DNA Set; Qiagen, Hilden, Germany). Sensitivity of the utilized primers and cycling conditions was defined by use of a dilution series in MSP assays, constituted of methylated DNA diluted with unmethylated DNA (50%, 10%, 1%, 0.1%, 0.01% and 0% methylation).

###### 

Oligonucleotide primers used in the study

  ----------------------------------------------------------------------------------------------------------------
                                   Sequence (5\' → 3\')                     T~A~\    Primer\   Product size (bp)
                                                                            \[°C\]   \[nM\]    
  -------------------------------- ---------------------------------------- -------- --------- -------------------
  ***Methylation-specific PCR***                                                               

                                                                                               

  *WIF1*unmethylated               Forward: GGGTGTTTTATTGGGTGTATTGT         55       400       154

                                   Reverse: AAAAAAACTAACACAAACAAAATACAAAC                      

                                                                                               

  *WIF1*methylated                 Forward: CGTTTTATTGGGCGTATCGT            55       400       145

                                   Reverse: ACTAACGCGAACGAAATACGA                              

                                                                                               

  *DKK3*unmethylated               Forward: TTAGGGGTGGGTGGTGGGGT            58       320       126

                                   Reverse: CTACATCTCCACTCTACACCCA                             

                                                                                               

  *DKK3*methylated                 Forward: GGGCGGGCGGCGGGGC                58       320       120

                                   Reverse: ACATCTCCGCTCTACGCCCG                               
  ----------------------------------------------------------------------------------------------------------------

T~A~, annealing temperature.

Statistical evaluations
-----------------------

Statistical analyses were completed using SPSS 14.0 (SPSS, Chicago, IL). Differences were considered significant when *P*-values were below 0.05. To study statistical associations between clinicopathological factors and methylation status contingency tables and two-sided Fisher\'s exact test were accomplished. In case of multiple statistical tests, the false discovery rate controlling procedure was applied. Survival curves were calculated using the Kaplan-Meier method, with significance evaluated by two-sided log-rank statistics. OS (n = 125) was measured from the day of surgery until breast cancer-related death (n = 21) and was censored for patients alive at last contact (n = 91), in case of death unrelated to the tumor (n = 5) or when the death cause was unknown (n = 8). DFS (n = 125) was measured from surgery until local or distant relapse (n = 30) and was censored for patients alive without evidence of relapse at the last follow-up (n = 95). A stepwise multivariate Cox regression model was adjusted, testing the independent prognostic relevance of clinical/investigational factors. The limit for reverse selection procedures was p = 0.1. Only patients for whom the status of all variables was known (n = 103) were included in the proportional hazard models. The proportionality assumption for all variables was assessed with log-negative-log survival distribution functions. The variables tumor size (pT), node status (pN) and histological grade (G) were dichotomised into less and more progressive groups (pT1-2 *vs*. pT3-4; pN0 *vs*. pN1-3; G1-2 *vs*. G3).

Results
=======

*WIF1*promoter methylation in primary breast carcinomas
-------------------------------------------------------

*WIF1*promoter methylation in human breast cancer has been previously reported by Ai *et al*. \[[@B11]\], who demonstrated, by use of MSP, *WIF1*methylation in 16 of 24 (67%) breast carcinoma samples. For three breast tumor specimens, these MSP results had also been confirmed by BGS. Unfortunately, in their study the *WIF1*promoter regions investigated by MSP and BGS were not matching or overlapping, so we decided to analyze *WIF1*promoter methylation in breast cancer by MSP in the particular promoter region that has been covered by BGS in the other study (Figure [1A](#F1){ref-type="fig"}). Initially, a dilution series of methylated DNA in an excess of unmethylated DNA (Epi Tect Control DNA, bisulfite-converted) was tested by MSP. This experiment determined the sensitivity of the utilized *WIF1*MSP assay to be 1.0% in the detection of methylated DNA molecules (\~0.1 ng) in a background of unmethylated DNA (\~9.9 ng) (Figure [1B](#F1){ref-type="fig"}). Next, *WIF1*promoter methylation was determined by MSP in 150 primary breast carcinoma specimens and also in 19 matching normal breast tissues. In all normal breast tissues, only unmethylated *WIF1*promoter sequence could be detected, as indicated by exclusive amplification with primers recognizing the unmethylated DNA sequence (Figure [2](#F2){ref-type="fig"}). In contrast, 95 of 150 primary breast carcinomas (63.3%) revealed a methylated *WIF1*promoter sequence, as indicated by amplification with primers specific to methylated DNA (Figure [2](#F2){ref-type="fig"}). The remaining 55 tumor specimens (36.7%) revealed solely unmethylated *WIF1*promoter sequence. In general, tumor samples, despite methylation, also revealed unmethylated *WIF1*promoter sequence, which is likely due to small contaminations with stromal and endothelial cells, as has also been previously described \[[@B34]\].

![**Methylation analysis of the human *WIF1*promoter**. (**A**) A 1.29 kb genomic sequence of the *WIF1*promoter, analyzed by methprimer software \[[@B29]\], revealed the presence of a CpG island (blue) between relative position 604 and 1153. Position 1000 indicates the transcription start site (TSS, arrow). A region of high CpG (red vertical bars) densitiy was chosen for MSP analysis. The black bar indicates the MSP amplicon. (**B**) Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA (Epi Tect control DNA, Qiagen). At least 1% of methylated DNA (\~0.1 ng) can be detected with the *WIF1*MSP primers. bp, base pair marker; NTC, \'no template control\'.](1471-2407-9-217-1){#F1}

![***WIF1*methylation in primary breast cancer**. *WIF1*methylation analyses of primary breast cancer specimens. MSP was performed on bisulfite-treated DNA from breast cancer (T) and matching normal primary breast tissues (N). MSP results from three representative matched pairs and eight additional breast carcinomas (\#) are shown. DNA bands in lanes labeled with U indicate MSP products amplified with primers recognizing the unmethylated promoter sequence. DNA bands in lanes labeled with M represent amplified MSP products with methylation-specific primers. Peripheral blood lymphocytes (PBL) and breast cancer cell line ZR75-1 served as positive controls for the methylation-specific reaction, respectively. Water was used as template in the \'no template control\' (NTC). Note that tumor tissue usually displayed a PCR product in the U-reaction as well, due to contaminating normal tissue (stromal cells, endothelial cells) present in the tumor specimens as has also been described by Suzuki *et al*. \[[@B34]\].](1471-2407-9-217-2){#F2}

*DKK3*promoter methylation in primary breast carcinomas
-------------------------------------------------------

We have recently reported of frequent *DKK3*promoter methylation in human breast cancer \[[@B13]\]. In the respective report, we have demonstrated that *DKK3*methylation was present in 61.3% of breast cancer patients (92 of 150), whereas in 19 matching normal breast tissues only one sample (5.3%) revealed faint methylation signals. Ideally, the samples analyzed for *WIF1*methylation in the present report were physically identical with the samples previously analyzed for *DKK3*methylation. The previously analyzed *DKK3*promoter region is pictured in Figure [3A](#F3){ref-type="fig"}. To allow a direct comparison between methylation of these two genes, we first assayed a dilution series of methylated DNA with unmethylated DNA by MSP using *DKK3*methylation-specific primers (see above). This experiment determined the sensitivity of the utilized *DKK3*MSP assay to be 1.0% in the detection of methylated DNA molecules (\~0.1 ng) in a background of unmethylated DNA (\~9.9 ng) (Figure [3B](#F3){ref-type="fig"}), thus enabling a subsequent correlation analysis in breast cancer employing the methylation results from both genes.

![**Methylation analysis of the human *DKK3*promoter**. (**A**) A 2.0 kb genomic sequence of the *DKK3*promoter, analyzed by methprimer software \[[@B29]\], revealed the presence of two CpG islands (blue); one between relative position 834 and 1261 and another one between position 1529 and 1917. Two alternative tissue-specific *DKK3*transcripts have been described \[[@B30]\]. Since transcription of the shorter transcript is widely distributed in normal tissues, we chose the region of the second transcription start site (TSS, arrow) for methylation analysis. Position 1000 indicates the alternative transcription start site of the longer transcript (TSS\*, arrow). A region of high CpG (red vertical bars) densitiy within the second CpG island was chosen for MSP analysis. (**B**) Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA (Epi Tect control DNA, Qiagen). At least 1% of methylated DNA (\~0.1 ng) can be detected with the *DKK3*MSP primers. bp, base pair marker; NTC, \'no template control\'.](1471-2407-9-217-3){#F3}

Association of *WIF1*and *DKK3*promoter methylation with clinicopathological parameters
---------------------------------------------------------------------------------------

For descriptive data analysis clinicopathological parameters were correlated with the *WIF1*and *DKK3*promoter methylation status. In a bivariate analysis, *WIF1*methylation was not associated with patient age at diagnosis, tumor size, lymph node status, histological grade, histological type, and estrogen or progesterone receptor status (Table [2](#T2){ref-type="table"}). *DKK3*methylation was associated with advanced patient age at diagnosis (p = 0.007), but not associated with any other of the investigated parameters (Table [2](#T2){ref-type="table"}).

###### 

Demographic/clinicopathological parameters in relation to *WIF1*and *DKK3*promoter methylation

                                                              *WIF1*methylation   *DKK3*methylation                                               
  ----------------------------------- ----------------------- ------------------- ------------------- --------- ------- ----- --------- --------- -------
  ***Clinicopathological factors***                                                                                                               
                                                                                                                                                  
  Age at diagnosis                                                                                                                                
                                      \<57 years              74                  32 (43)             42 (57)   0.127   74    37 (50)   37 (50)   0.007
                                      ≥ 57 years              76                  23 (30)             53 (70)           76    21 (28)   55 (72)   
                                                                                                                                                  
  Tumor size^3^                                                                                                                                   
                                      pT1-pT2                 129                 48 (37)             81 (63)   1.000   129   52 (40)   77 (60)   0.440
                                      pT3-pT4                 18                  7 (39)              11 (61)           18    5 (28)    13 (72)   
                                                                                                                                                  
  Lymph node status^3^                                                                                                                            
                                      pN0                     72                  29 (40)             43 (60)   0.606   72    32 (44)   40 (56)   0.170
                                      pN1-pN3                 71                  25 (35)             46 (65)           71    23 (32)   48 (67)   
                                                                                                                                                  
  Histological grade                                                                                                                              
                                      G1-G2                   88                  28 (32)             60 (68)   0.170   88    31 (35)   57 (65)   0.313
                                      G3                      62                  27 (44)             35 (57)           62    27 (44)   35 (57)   
                                                                                                                                                  
  Histological type                                                                                                                               
                                      IDC                     122                 43 (35)             79 (65)           122   45 (37)   77 (63)   
                                      lobular                 19                  7 (37)              12 (63)   0.296   19    7 (37)    12 (63)   0.236
                                      other                   9                   5 (56)              4 (44)            9     6 (67)    3 (33)    
                                                                                                                                                  
  *Immunohistochemistry*                                                                                                                          
                                                                                                                                                  
  Estrogen receptor                                                                                                                               
                                      negative (IRS^4^0--2)   47                  21 (45)             26 (55)   0.142   47    20 (43)   27 (57)   0.467
                                      positive (IRS 3--12)    98                  31 (32)             67 (68)           98    35 (36)   63 (64)   
                                                                                                                                                  
  Progesterone receptor                                                                                                                           
                                      negative (IRS^4^0--2)   51                  22 (43)             29 (57)   0.206   51    21 (41)   30 (59)   0.593
                                      positive (IRS 3--12)    94                  30 (32)             64 (68)           94    34 (36)   60 (64)   
                                                                                                                                                  
  *WIF1 promoter*                                                                                                                                 
                                                                                                                                                  
                                      unmethylated            \-                  \-                  \-        \-      55    29 (53)   26 (47)   0.009
                                      methylated              \-                  \-                  \-                95    29 (31)   66 (69)   

^1^Only female patients with primary, unilateral invasive breast cancer were included. ^2^Fisher\'s exact test. ^3^According to UICC: TNM Classification of Malignant Tumours \[[@B25]\]. ^4^IRS, immunoreactivity score according to Remmele and Stegner \[[@B27]\]. Percentages may not sum to 100 due to rounding. IDC, invasive ductal carcinoma; n.a., not available.

Correlation of *WIF1*and *DKK3*promoter methylation in primary breast carcinoma
-------------------------------------------------------------------------------

In a bivariate analysis, methylation of the *WIF1*promoter was significantly associated with methylation of the *DKK3*promoter (p = 0.009) (Table [2](#T2){ref-type="table"}). Both gene promoters were mutually unmethylated in tumors from 29 of 150 patients (19.3%) and mutually methylated in tumors from 66 of 150 patients (44.0%) (Figure [4](#F4){ref-type="fig"}). For 55 of 150 patients (36.7%) the methylation status of the *WIF1*and *DKK3*promoter differed: *WIF1*methylation together with *DKK3*non-methylation was detected in 29/250 patients (19.3%), whereas *WIF1*non-methylation together with *DKK3*methylation was detected in 26 of 150 patients (17.3%).

![**Distribution of *WIF1*and *DKK3*promoter methylation in primary breast carcinomas**. Methylation status of either gene has been determined by MSP in the same tumors. Of n = 150 breast cancer patients, the larger fraction reveals an identical methylation status of both genes (63.3%). In the remaining smaller fraction (36.6%), methylation of only one of the two genes could be detected. In total, *WIF1*methylation was significantly associated with *DKK3*methylation (p = 0.009; Fisher\'s exact test).](1471-2407-9-217-4){#F4}

Association of *WIF1*promoter methylation with patient survival
---------------------------------------------------------------

Patient OS and DFS were compared between methylated *versus*unmethylated *WIF1*promoter sequence by univariate Kaplan-Meier analysis using log-rank statistics. In this analysis, *WIF1*methylation was not significantly associated with patient OS (p = 0.656) or patient DFS (p = 0.154) (Table [3](#T3){ref-type="table"}), as also demonstrated by Kaplan-Meier survival curves (Figure [5](#F5){ref-type="fig"}). As expected, a positive lymph node status (pN1-3) and higher histological grade (G3) were found to be associated with decreased OS (p = 0.002; p = 0.001) and DFS (p \< 0.001; p = 0.012).

###### 

Univariate survival analysis of clinicopathological and molecular factors (log-rank test)

  Variable                            Categorization          Overall survival   Disease-free survival                        
  ----------------------------------- ----------------------- ------------------ ----------------------- --------- ----- ---- ---------
  ***Clinicopathological factors***                                                                                           
                                                                                                                              
  Age at diagnosis                                                                                                            
                                      \<57 years              64                 7                       0.094     64    16   0.711
                                      ≥ 57 years              61                 14                                61    14   
                                                                                                                              
  Tumor size^3^                                                                                                               
                                      pT1-pT2                 107                17                      0.372     107   25   0.427
                                      pT3-pT4                 16                 4                                 16    5    
                                                                                                                              
  Lymph node status^3^                                                                                                        
                                      pN0                     54                 3                       0.002     54    5    \<0.001
                                      pN1-pN3                 65                 18                                65    24   
                                                                                                                              
  Histological grade                                                                                                          
                                      G1-G2                   72                 5                       0.001     72    11   0.012
                                      G3                      53                 16                                53    19   
  Histological type                                                                                                           
                                      IDC                     101                19                      0.267     101   22   0.277
                                      other                   24                 2                                 24    8    
                                                                                                                              
  *Immunohistochemistry*                                                                                                      
                                                                                                                              
  Estrogen receptor                                                                                                           
                                      negative (IRS^4^0--2)   40                 9                       0.155     40    9    0.962
                                      positive (IRS 3--12)    80                 12                                80    21   
                                                                                                                              
  Progesterone receptor                                                                                                       
                                      negative (IRS^4^0--2)   39                 9                       0.154     39    13   0.087
                                      positive (IRS 3--12)    81                 12                                81    17   
                                                                                                                              
  *WIF1 promoter*                                                                                                             
                                                                                                                              
                                      unmethylated            47                 9                       0.656     47    8    0.154
                                      methylated              78                 12                                78    22   
                                                                                                                              
  *DKK3 promoter*                                                                                                             
                                                                                                                              
                                      unmethylated            46                 1                       \<0.001   46    7    0.037
                                      methylated              79                 20                                79    23   

^1^Only female patients with primary, unilateral invasive breast cancer were included. ^2^Log-rank test. ^3^According to UICC: TNM Classification of Malignant Tumours \[[@B25]\]. ^4^IRS, immunoreactivity score according to Remmele and Stegner \[[@B27]\]. IDC, invasive ductal carcinoma.

![**Univariate Kaplan-Meier survival analysis of breast cancer patients in relation to *WIF1*and *DKK3*promoter methylation**. (**A**) Overall survival and (**B**) disease-free survival are not associated with *WIF1*promoter methylation in human breast cancer. Solid lines indicate methylated *WIF1*promoter; dotted lines indicate unmethylated *WIF1*promoter in the tumor. (**C**) In contrast, methylation of the *DKK3*promoter in tumor tissue (solid line) is significantly associated with adverse patient overall survival, whereas patients with an unmethylated *DKK3*promoter in the tumor tissue have a very favorable clinical outcome (dotted line) (p \< 0.001). (**D**) In addition, *DKK3*-methylated tumors reveal a significant shorter time to recurrence (solid line), as compared to tumors harboring an unmethylated *DKK3*promoter (dotted line) (p = 0.037). Vertical tick marks represent censored patients.](1471-2407-9-217-5){#F5}

Association of *DKK3*promoter methylation with patient survival
---------------------------------------------------------------

Patient OS and DFS were compared between methylated *versus*unmethylated *DKK3*promoter sequence. In contrast to *WIF1*methylation, *DKK3*methylation was significantly associated with poor OS (5-year survival: 75% for cases with methylated alleles *vs*. 97% for cases with unmethylated alleles; 10-year survival: 54% *vs*. 97%; p = 0.0005; Table [3](#T3){ref-type="table"}) and shorter DFS (5-year survival: 67% for cases with methylated alleles *vs*. 84% for cases with unmethylated alleles; 10-year-survival: 58% *vs*. 78%; p = 0.037; Table [3](#T3){ref-type="table"}), as also illustrated by Kaplan-Meier survival curves (Figure [5](#F5){ref-type="fig"}). Based on a mean OS of 141 months (95% CI: 127--154 months) patients without *DKK3*methylation in the tumor tissue revealed much longer mean OS (170 months, 95% CI: 163--177 months) than patients with *DKK3*methylation in the tumor tissue (113 months, 95% CI: 95--131 months). Based on a mean DFS of 99 months (95% CI: 90--107 months) patients without *DKK3*methylation in the tumor revealed longer mean DFS (110 months, 95% CI: 99--122 months) than patients with *DKK3*methylation in the tumor (86 months, 95% CI: 75--97 months). Multivariate Cox regression models were calculated and adjusted to assess factor-related hazard risks and to test for independency of *DKK3*methylation as a prognostic factor in patient OS and DFS. The strength of the association between *DKK3*methylation and unfavourable patient outcome is presented in Table [4](#T4){ref-type="table"} and Table [5](#T5){ref-type="table"}. Multivariate, *DKK3*methylation in breast carcinoma represented an independent and strong risk factor for OS (HR: 14.4; 95% CI: 1.9 -- 111.6; p = 0.011; Table [4](#T4){ref-type="table"}). In DFS the prognostic potency of *DKK3*methylation was weaker than in OS (HR: 2.5; 95% CI: 1.0 -- 6.0; p = 0.047; Table [5](#T5){ref-type="table"}).

###### 

Multivariate Cox regression analysis of *DKK3*promoter methylation with regard to overall survival

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                         Multivariate analysis\   Multivariate analysis\                                                       
                                                         Overall survival\        Overall survival\                                                            
                                                         (global model)           (reverse selection procedure^2^)                                             
  ----------------------- -------------- --------------- ------------------------ ---------------------------------- --------------- --------- --------------- -------
  **Variable**            **HR**         **95% CI^1^**   ***P***                  **HR**                             **95% CI^1^**   ***P***                   

                                                                                                                                                               

  Age at diagnosis        \<57 years     0               1.0                                                                         1.0                       

                          ≥ 57 years     1               1.78                     0.63 -- 4.99                       0.276           2.27      0.85 -- 6.07    0.104

                                                                                                                                                               

  Tumor size              pT1-2          0               1.0                                                                                                   

                          pT3-4          1               0.83                     0.25 -- 2.78                       0.766                                     

                                                                                                                                                               

  Lymph nodes             pN0            0               1.0                                                                         1.0                       

                          pN1-3          1               5.47                     1.46 -- 20.53                      0.012           4.50      1.26 -- 15.87   0.021

                                                                                                                                                               

  Histological grade      G1             0               1.0                                                                         1.0                       

                          G2-G3          1               4.36                     1.54 -- 12.40                      0.006           4.50      1.57 -- 12.87   0.005

                                                                                                                                                               

  Histological type       ductal         0               1.0                                                                                                   

                          other          1               0.46                     0.09 -- 2.22                       0.330                                     

                                                                                                                                                               

  Estrogen receptor       negative       0               1.0                                                                         1.0                       

                          positive       1               0.51                     0.18 -- 1.47                       0.214           0.43      0.17 -- 1.09    0.426

                                                                                                                                                               

  Progesterone receptor   negative       0               1.0                                                                                                   

                          positive       1               0.57                     0.21 -- 1.54                       0.270                                     

                                                                                                                                                               

  *DKK3*promoter          unmethylated   0               1.0                                                                         1.0                       

                          methylated     1               14.41                    1.86 -- 111.56                     0.011           13.68     1.77--105.52    0.012
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Confidence interval (CI) on the estimated hazard ratio (HR). ^2^Only terms that remained in the model after reverse selection are listed. All variables were stratified binary according to Table 3.

###### 

Multivariate Cox regression analysis of *DKK3*promoter methylation with regard to disease-free survival

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                         Multivariate analysis\   Multivariate analysis\                                                       
                                                         Disease-free survival\   Disease-free survival\                                                       
                                                         (global model)           (reverse selection procedure^2^)                                             
  ----------------------- -------------- --------------- ------------------------ ---------------------------------- --------------- --------- --------------- -------
  **Variable**            **HR**         **95% CI^1^**   ***P***                  **HR**                             **95% CI^1^**   ***P***                   

                                                                                                                                                               

  Age at diagnosis        \<57 years     0               1.0                                                                                                   

                          ≥ 57 years     1               0.57                     0.24 -- 1.33                       0.191                                     

                                                                                                                                                               

  Tumor size              pT1-2          0               1.0                                                                                                   

                          pT3-4          1               0.61                     0.22 -- 1.72                       0.353                                     

                                                                                                                                                               

  Lymph nodes             pN0            0               1.0                                                                         1.0                       

                          pN1-3          1               4.24                     1.50 -- 11.96                      0.006           4.01      1.49 -- 10.81   0.006

                                                                                                                                                               

  Histological grade      G1             0               1.0                                                                         1.0                       

                          G2-G3          1               2.01                     0.91 -- 4.43                       0.086           1.93      0.88 -- 4.24    0.102

                                                                                                                                                               

  Histological type       IDC            0               1.0                                                                                                   

                          other          1               1.04                     0.42--2.62                         0.929                                     

                                                                                                                                                               

  Estrogen receptor       negative       0               1.0                                                                                                   

                          positive       1               2.17                     0.78 -- 6.03                       0.137                                     

                                                                                                                                                               

  Progesterone receptor   negative       0               1.0                                                                         1.0                       

                          positive       1               0.36                     0.15 -- 0.88                       0.025           0.53      0.25 -- 1.11    0.091

                                                                                                                                                               

  *DKK3*promoter          unmethylated   0               1.0                                                                         1.0                       

                          methylated     1               2.46                     1.01 -- 5.97                       0.047           2.08      0.88 -- 4.88    0.094
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Confidence interval (CI) on the estimated hazard ratio (HR). ^2^Only terms that remained in the model after reverse selection are listed. All variables were stratified binary according to Table 3.

Discussion
==========

It was previously reported that expression of the Wnt antagonist genes *WIF1*and *DKK3*is downregulated in several tumor entities as a consequence of epigenetic DNA modification \[[@B11],[@B13],[@B21],[@B31],[@B35],[@B36]\]. WIF1 is a conserved Wnt-binding protein that prevents Wnt ligands from interacting with membranous frizzled receptors, thus may inhibit activation of the Wnt/β-catenin signaling cascade \[[@B37]\]. In breast, lung, prostate and bladder cancer, WIF1 expression was found to be frequently downregulated \[[@B38]\], suggesting it might represent a tumor suppressor gene. In breast cancer, this downregulation could be attributed to hypermethylation of the *WIF1*promoter \[[@B11]\], as demonstrated both in breast cell lines and in primary breast carcinomas. In our study, methylation of the *WIF1*promoter was detected in 63% of invasive tumors from breast cancer patients, thus being in good agreement with previous results from Ai *et al*. \[[@B11]\], who reported a frequency of 67% for *WIF1*methylation in mammary tumors. Differences may arise through different sample sizes (n = 150 and n = 24) as well as different promoter locations assessed in either study. DKK3 is a further secreted inhibitor of Wnt signaling, but in contrast to WIF1 does not sequester Wnt ligands. The actual mechanism by which DKK3 acts inhibitory on Wnt pathway activation has not been identified yet, but suppression of DKK3 increased β-catenin/T-cell factor (TCF)-dependent gene activity in mammary cells \[[@B39]\], cancerous lung cells \[[@B40]\] and glioma \[[@B41]\]. Likewise to *WIF1*, the *DKK3*gene was also reported as a frequent target of epigenetic inactivation in numerous tumor entities, *e.g*. in lung cancer, prostate cancer and leukemia \[[@B21],[@B31],[@B42]\], suggesting that DKK3 may exert tumor suppressive functions. In a recent report, we have demonstrated that *DKK3*is frequently inactivated in invasive breast carcinomas by promoter methylation leading to loss of DKK3 expression \[[@B13]\]. This epimutation affected 92 of 150 investigated breast cancer patients (61%). Since these samples were identical to the samples for which we now have determined *WIF1*methylation, we were able to perform a combined analysis of both genes\' methylation in breast cancer.

In a bivariate analysis, *WIF1*methylation status in breast carcinomas was significantly associated with the *DKK3*methylation status. Despite, within the cohort of carcinomas being affected by methylation of either the *DKK3*or *WIF1*gene, a large fraction (45%) showed methylation in one gene only. This demonstrates that in spite of a statistical association between methylation of the two genes, there is still a large fraction of breast cancer patients with different *DKK3/WIF1*methylation pattern. Therefore, it is unlikely that methylation of both Wnt antagonist genes is a mandatory mutual carcinogenic event. In a further correlation analysis, neither of the two genes was associated with relevant clinicopathological features, except for *DKK3*methylation being associated with advanced patient age. Age-dependent promoter methylation has been reported previously \[[@B43],[@B44]\] and may randomly overlay the effects of gene-specific promoter methylation that can lead to the development of distinct cancer subtypes. The absence of an association between *WIF1*or *DKK3*methylation with important clinicopathological factors like tumor size, histological grade and lymph node invasion strongly suggests that methylation of either gene is an early carcinogenic event in breast cancer development, rather than contributing to tumor progression.

Most important, major differences between *WIF1*and *DKK3*methylation arise in their association with breast cancer patient survival. *WIF1*methylation showed no significance in clinical patient outcome in contrast to *DKK3*methylation, which was tightly associated with adverse patient OS and weaker with short DFS in our study. Patients harboring *DKK3*methylation in the tumor had a poor prognosis (54% chance of 10-years OS) in contrast to patients retaining an unmethylated *DKK3*promoter, who had a favorable prognosis (97% chance of 10-years OS). This finding was supported by a multivariate Cox regression analysis in which *DKK3*-methylated patients revealed a high risk of tumor-related death (HR: 14.4). Hence, this parameter outperformed classical prognostic factors in our patient cohort, *i.e*. high histological grade (HR: 4.4) or a positive lymph node status (HR: 5.5). Unproportional HRs of high impact were rarely achieved even in studies with very large sample size numbers, neither by strong conventional factors like node status (HR: 2.4) \[[@B45]\] and grade (HR: 5.7) \[[@B46]\] nor by investigational factors like the tissue urokinase-type plasminogen activator/inhibitor (uPA/PAI), which in case of high level exposes patients to a five times greater risk of dying from breast cancer \[[@B47]\]. In conclusion, our results demonstrate that determination of the *DKK3*methylation status may provide valuable information to aid prognostication in the clinical management of breast cancer patients. Notably, methylation of the *DKK3*promoter was recently shown to be prognosis relevant also in other tumor entities, such as in acute lymphoblastic leukemia, kidney cancer, lung cancer, and gastric cancer \[[@B21]-[@B24]\], pointing to a potential clinical use of this marker in several cancer diseases.

Our findings raise expectations towards translation of such methylation markers into clinical practice. As an example, *DKK3*may be a prime candidate gene to be incorporated into diagnostic multimarker panels, for its aberrant methylation is specific to malignant cells in breast cancer \[[@B13]\]. Preliminary results from our laboratory revealed that *DKK3*methylation can be detected with high clinical sensitivity and specificity in blood serum of breast cancer patients independent of tumor size and node status (unpublished data). The presence of detectable tumor DNA in serum is generally associated with poor prognosis \[[@B48],[@B49]\], and taken together with its marker performance in solid breast tumor tissue, *DKK3*methylation fulfils essential prerequisites as a biomarker in a blood-borne assay, of which we will report in a future study.

In summary, we here demonstrate that although *WIF1*and *DKK3*promoter methylation are similar frequent alterations in human breast cancer, only *DKK3*methylation appears to be a survival risk factor for breast cancer patients and thus might be useful as prognostic marker in clinical oncology helping to improve patient outcome.

Conclusion
==========

This study shows that the Wnt antagonist gene *WIF1*is frequently inactivated by promoter hypermethylation in human breast cancer. Although *WIF1*is similarly frequent hypermethylated like the Wnt antagonist gene *DKK3*, and neither gene methylation is associated with relevant clinicopathological factors, *DKK3*methylation is an independent prognostic factor in breast cancer patient survival, whereas *WIF1*methylation is not. These differences may reflect subtle distinctions in the biological roles of the two related molecules in inhibiting Wnt/β-catenin signaling.
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